Patient-Focused Drug Discovery Meeting at the FDA on Huntington’s Disease
On Tuesday, September 22nd, 2015, the U.S. Food and Drug Administration will be hosting a patient-focused meeting on Huntington’s disease drug development for the American HD community. This meeting is an exciting one-of-a-kind opportunity for HD patients and caregivers to bring their voices directly to the FDA to inform the HD drug development process. Specifically, the FDA wants to hear about the HD symptoms that most impact HD families and what the families want in new treatments for HD.
As the result of a generous educational grant from Teva Pharmaceuticals, the Huntington’s Disease Society of America is pleased to announce that we will be providing hotel accommodations for HD patients and caregivers who have registered to attend the FDA meeting to ease the financial burden of attending this important forum. Resources are limited, so accommodations will be allocated on a first come, first served basis, and are only available to those who have registered with the FDA to attend the event in-person. (Participation by webcast is also available for folks who are unable to travel.)
To take advantage of this opportunity, please fill out the information below and then click on the FDA meeting registration link to qualify for accommodations for the night of Monday, September 21st, 2015.
A member of the HDSA staff team will contact you within 2 business days of your submission to confirm your room.
FDA Meeting Registration: https://www.eventbrite.com/e/huntingtons-and-parkinsons-disease-patient-focused-drug-development-public-meeting-registration-17411273588